Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Regular price $3,495.00 Sale

Published on May 30, 2014 - 45 pages

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Abilify (aripiprazole) is an atypical antipsychotic indicated for use as an adjunctive treatment for MDD in patients who have not adequately responded to antidepressant therapy in the US. Abilify is available in the 5EU, Japan, and Australia, but is not indicated for the treatment of MDD, and as such, it is being used as an off-label treatment, as validated by GlobalData's primary research survey in January 2014.

Scope
  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abilify including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abilify for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Abilify performance
  • Obtain sales forecast for Abilify from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)


Table of Contents

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms and Subtypes of Major Depressive Disorder
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
6 Abilify (Aripiprazole)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed MDD Patients
7.4.2 Percent of Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 About the Authors
7.6.1 Analyst
7.6.2 Therapy Area Directors
7.6.3 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
Table 2: Subtypes of Major Depressive Disorder
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
Table 4: Treatment Guidelines for Major Depressive Disorder
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
Table 6: Leading Treatments for MDD, 2013
Table 7: Product Profile - Abilify
Table 8: Safety of Abilify - Five Most Frequently Reported Adverse Events
Table 9: Abilify SWOT Analysis, 2014
Table 10: Global MDD Sales Forecasts ($m) for Abilify, 2013-2023
Table 11: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

1.2 List of Figures
Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
Figure 2: Disease Management Model for Major Depressive Disorder
Figure 3: Major Depressive Disorder Treatment Algorithm